Serplulimab

Serplulimab is Shanghai Henlius Biotech's anti-PD-1 antibody, marketed in China as Hansizhuang and already approved by the NMPA for MSI-H (microsatellite instability-high, a DNA mismatch-repair defect that predicts strong checkpoint response) solid tumors and extensive-stage small cell lung cancer [1][2]. NCT06419673 tests it as an add-on to chemoradiotherapy in FIGO 2018 stage III-IVA cervical cancer (locally advanced disease that has spread within the pelvis but not to distant organs), a setting where pembrolizumab established the paradigm with KEYNOTE-A18 [3]. The commercial question is whether Henlius and its US partner Fosun Pharma can extend a cheaper China-origin PD-1 into indications currently dominated by Merck.

Serplulimab has a split identity. It is an approved drug in China (NMPA 2022 for MSI-H solid tumors, 2023 for ES-SCLC) with a commercial brand, Hansizhuang, but remains a pipeline asset for cervical cancer and for most Western markets. There are no active FDA approvals, and no breakthrough or fast-track designations are on record. In Europe, serplulimab received EC approval in first-line ES-SCLC in February 2025 and has since added several indications [8]. Fosun Pharma USA is the disclosed US development partner, and Henlius has completed enrollment in a US bridging study comparing serplulimab head-to-head with atezolizumab in ES-SCLC to support a future FDA submission [8]. The specific trial referenced here, NCT06419673, is a Phase 2 study combining serplulimab with chemoradiotherapy in stage III-IVA cervical cancer [4]; the ClinicalTrials.gov registry does not confirm the primary endpoint or enrollment target. Broader development spans the ASTRUM program: ASTRUM-005 posted positive overall survival in ES-SCLC (median OS 15.8 vs 11.1 months, HR 0.60) [9], ASTRUM-002 published final survival for nonsquamous NSCLC in 2026 (OS HR 0.66, 95% CI 0.52-0.83) [5], and ASTRUM-CC01 recently reported Phase 2 data for serplulimab plus bevacizumab (an antibody that blocks VEGF and starves tumors of blood supply) and chemotherapy in recurrent or metastatic cervical cancer [1]. A separate real-world validation study confirmed the ASTRUM-005 OS signal in Chinese practice [6]. No specific readout date has been announced for NCT06419673. For Western regulators, the decisive event will be the US bridging study readout in ES-SCLC, not additional Chinese single-country registration trials.

Serplulimab is a humanized IgG4 monoclonal antibody that binds PD-1, a receptor on T cells that acts like a brake pedal on the immune system. Tumors exploit this brake by expressing PD-L1, which docks into PD-1 and tells nearby T cells to stand down. Blocking PD-1 releases the brake and lets T cells attack the tumor. The mechanism is among the most heavily validated in oncology, with approved anti-PD-1 antibodies from Merck (pembrolizumab), BMS (nivolumab), and multiple Chinese developers (tislelizumab, sintilimab, camrelizumab, toripalimab). Serplulimab is not mechanistically novel. The commercial thesis rests on price, geographic expansion, and combination strategies. Cervical cancer is a rational indication because HPV-driven tumors carry a high viral and mutational antigen load, so once the PD-1 brake is off, T cells have plenty of targets to recognize. Pembrolizumab's KEYNOTE-A18 trial already showed that adding a PD-1 inhibitor to chemoradiotherapy in locally advanced cervical cancer improves progression-free survival (HR 0.70, 95% CI 0.55-0.89) and overall survival (HR 0.67, 95% CI 0.50-0.90) [3], which is the paradigm serplulimab is trying to enter. The scientific question is not whether the mechanism works in this setting; it works. The question is whether serplulimab can differentiate on price, tolerability, or subgroup performance against an entrenched Merck standard.

NCT06419673 is a Phase 2, multicenter, randomized, open-label study testing serplulimab plus chemoradiotherapy versus chemoradiotherapy alone in FIGO 2018 stage III or IVA cervical cancer [4]. Randomization and an active comparator arm are the right choices, and the design directly mirrors the pembrolizumab KEYNOTE-A18 template that established the standard of care in this setting [3]. As a Phase 2, it is likely powered for progression-free survival or a shorter-term efficacy signal rather than overall survival, though the exact primary endpoint and enrollment target were not confirmed in the available registry data. The sponsor of record is a Chinese academic center, with Henlius supplying drug. In parallel, a larger and more commercially decisive study, NCT07739758, is a Phase 3 recruiting 442 patients to test the antibody-drug conjugate (ADC - an antibody engineered to deliver a chemotherapy payload directly to tumor cells expressing a specific surface protein) YL201 from MediLink Therapeutics combined with serplulimab as first-line treatment in ES-SCLC, with overall survival as the primary endpoint [7]. The trial is in early recruitment and a primary completion date has not been publicly disclosed at the level of registry detail we can confirm. That trial is arguably a bigger signal than the cervical Phase 2, because it stress-tests whether serplulimab can serve as the immune backbone for next-generation combinations in an indication where it is already the incumbent PD-1 in China.

Our model estimates a 4% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 13%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by larger-than-typical enrollment for this phase; it is held back by the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is low on mechanism but real on differentiation. If serplulimab plus chemoradiotherapy shows a smaller PFS benefit than pembrolizumab did in KEYNOTE-A18 (HR 0.70), the commercial case collapses because clinicians already have a proven option [3]. Safety risk is class-typical: immune-related adverse events including colitis, pneumonitis, and endocrinopathies that all PD-1 antibodies share. Nothing atypical has been reported for serplulimab specifically. Execution risk is elevated for Western markets. Fosun and Henlius have limited FDA regulatory experience compared to Merck or BMS, and Henlius has responded by running a US head-to-head bridging study against atezolizumab in ES-SCLC to build a US-acceptable data package before filing [8]. Commercial risk is the biggest hurdle. In the US and EU, pembrolizumab is entrenched, has broader label coverage, and faces biosimilar competition after 2028 anyway, which will squeeze the pricing headroom for late entrants. In China, the PD-1 market is a price war. Tislelizumab, sintilimab, camrelizumab, and toripalimab all compete on volume-based procurement contracts at heavily discounted per-dose prices. Public NRDL-negotiated prices for domestic Chinese PD-1s have fallen into the low-single-thousands RMB per vial range, roughly an order of magnitude below imported pembrolizumab's list price, though exact per-patient-year cost comparisons vary by dosing and payer mix and are not publicly disclosed for serplulimab at a level supporting a confident dollar figure. Growth depends on winning indication expansion faster than the competition while defending the existing SCLC and MSI-H franchises.

The ASTRUM cervical and lung readouts the earlier draft told readers to wait for have now reported. ASTRUM-CC01 (Phase 2, serplulimab + bevacizumab + chemo in recurrent/metastatic cervical) is published [1], and ASTRUM-002 final survival in nonsquamous NSCLC posted an OS HR of 0.66 (95% CI 0.52-0.83) with roughly four years of follow-up [5]. Both support that serplulimab is a real anti-PD-1 with real efficacy, not just a discount clone. The next live catalysts to watch are: (1) NCT06419673 first readout, where the bar to matter is a PFS hazard ratio at least in the neighborhood of KEYNOTE-A18's 0.70, ideally with cleaner tolerability [3]; (2) NCT07739758, the MediLink YL201 ADC plus serplulimab in first-line ES-SCLC, which tests whether serplulimab can be the immune backbone for next-generation combinations in an indication it already owns in China [7]; and (3) Fosun/Henlius disclosures on the US ES-SCLC bridging study readout and any subsequent FDA submission - that is the decisive commercial gate for Western entry [8]. Without the US bridging study succeeding and a Western partner big enough to fight Merck on formulary access, the ceiling is a strong China franchise, an emerging EU footprint, and modest opportunistic sales elsewhere. Worth watching, not urgent.